Literature DB >> 11741161

Residual HIV-1 disease in seminal cells of HIV-1-infected men on suppressive HAART: latency without on-going cellular infections.

Giuseppe Nunnari1, Miguel Otero, Geethanjali Dornadula, Michelle Vanella, Hui Zhang, Ian Frank, Roger J Pomerantz.   

Abstract

BACKGROUND: HIV-1-infected men on suppressive highly active antiretroviral therapy (HAART) have a reduction of viral replication in vivo, but HIV-1 RNA is still detectable by certain ultrasensitive reverse transcriptase-PCR assays in blood plasma. Replication-competent virus can also be isolated from both peripheral blood mononuclear cells (PBMC) and seminal cells of these patients. Despite HAART, on-going in vivo infection of HIV-1-seropositive patients' PBMC was demonstrated by the detection of episomal HIV-1 moieties, known as HIV-1 two-long terminal repeat (2-LTR) DNA circles.
METHODS: The present study analyzes whether new cellular infections occur in vivo in seminal cells of HIV-1-infected men on suppressive HAART. PBMC and seminal cells were isolated from a cohort of HIV-1-seropositive men taking suppressive HAART (< 50 copies HIV RNA/ml blood plasma). Viral growth assays were performed in vitro, as well as semi-quantitative PCR to detect HIV-1 2-LTR circular DNA in PBMC and seminal mononuclear cells.
RESULTS: Viral growth in vitro was demonstrated in 16 out of 28 (57%) patients' PBMC, and in five patients' seminal cells (18%). Although 18 patients' PBMC were positive for HIV-1 2-LTR DNA circles, importantly, 2-LTR circular DNA was not detected in any semen sample, even when replication-competent HIV-1 virus had been recovered from a patient's seminal cells by viral co-culture assays.
CONCLUSIONS: The current study suggests that in HIV-1-infected men treated with suppressive HAART, new cellular infections occur in PBMC, but that new infections do not take place in seminal cells in vivo. Thus, these findings suggest that mainly latent HIV-1 occurs in seminal cells of men on suppressive HAART, which may be a compartment-specific mechanism of residual HIV-1 disease.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11741161     DOI: 10.1097/00002030-200201040-00006

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  12 in total

Review 1.  Use of assisted reproductive technology to reduce the risk of transmission of HIV in discordant couples wishing to have their own children where the male partner is seropositive with an undetectable viral load.

Authors:  H W G Baker; A Mijch; S Garland; S Crowe; M Dunne; D Edgar; G Clarke; P Foster; J Blood
Journal:  J Med Ethics       Date:  2003-12       Impact factor: 2.903

2.  The second wave will drown us.

Authors:  Michael Gross
Journal:  Am J Public Health       Date:  2003-06       Impact factor: 9.308

3.  Detection of Simian Immunodeficiency Virus in Semen, Urethra, and Male Reproductive Organs during Efficient Highly Active Antiretroviral Therapy.

Authors:  G Matusali; N Dereuddre-Bosquet; A Le Tortorec; M Moreau; A-P Satie; D Mahé; P Roumaud; O Bourry; N Sylla; S Bernard-Stoecklin; A Pruvost; R Le Grand; N Dejucq-Rainsford
Journal:  J Virol       Date:  2015-04-01       Impact factor: 5.103

Review 4.  Targeting Trojan Horse leukocytes for HIV prevention.

Authors:  Deborah J Anderson; Joseph A Politch; Adam M Nadolski; Caitlin D Blaskewicz; Jeffrey Pudney; Kenneth H Mayer
Journal:  AIDS       Date:  2010-01-16       Impact factor: 4.177

5.  In a subset of subjects on highly active antiretroviral therapy, human immunodeficiency virus type 1 RNA in plasma decays from 50 to <5 copies per milliliter, with a half-life of 6 months.

Authors:  Michele Di Mascio; Geethanjali Dornadula; Hui Zhang; Julie Sullivan; Yan Xu; Joseph Kulkosky; Roger J Pomerantz; Alan S Perelson
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

6.  Genital tract sequestration of SIV following acute infection.

Authors:  James B Whitney; Peter T Hraber; Corinne Luedemann; Elena E Giorgi; Marcus G Daniels; Tanmoy Bhattacharya; Srinivas S Rao; John R Mascola; Gary J Nabel; Bette T Korber; Norman L Letvin
Journal:  PLoS Pathog       Date:  2011-02-17       Impact factor: 6.823

7.  Impact of short-term HAART initiated during the chronic stage or shortly post-exposure on SIV infection of male genital organs.

Authors:  Marina Moreau; Anna Le Tortorec; Claire Deleage; Charles Brown; Hélène Denis; Anne-Pascale Satie; Olivier Bourry; Nathalie Deureuddre-Bosquet; Pierre Roques; Roger Le Grand; Nathalie Dejucq-Rainsford
Journal:  PLoS One       Date:  2012-05-17       Impact factor: 3.240

8.  Human immunodeficiency virus type-1 episomal cDNA in semen.

Authors:  Chong Xu; Joseph A Politch; Kenneth H Mayer; Deborah J Anderson
Journal:  AIDS Res Ther       Date:  2005-10-11       Impact factor: 2.250

9.  HIV in semen: still more to be learned.

Authors:  Pietro L Vernazza
Journal:  AIDS Res Ther       Date:  2005-12-03       Impact factor: 2.250

Review 10.  Nanoparticles containing siRNA to silence CD4 and CCR5 reduce expression of these receptors and inhibit HIV-1 infection in human female reproductive tract tissue explants.

Authors:  Susan K Eszterhas; Nicole O Ilonzo; Jennifer E Crozier; Stela Celaj; Alexandra L Howell
Journal:  Infect Dis Rep       Date:  2011-09-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.